# BARDA Awards SCYNEXIS Antifungal Contract

BARDA awarded SCYNEXIS a cost-share contract announced September 28, 2026, to advance SCY-247, an oral and intravenous antifungal candidate. The contract provides approximately **$18.5 million** for the base period, which began in September 2026, and has a potential ceiling of **$214 million** if BARDA exercises discretionary options over as long as 10 years. The award supports drug development, potentially through regulatory submissions; the full ceiling is not committed funding, and the announcement describes an award rather than an open solicitation.

- Suppliers and prospective subcontractors can assess whether their capabilities align with SCYNEXIS’s development work; the signals do not identify a specific subcontracting opportunity or action for other bidders.
- The potential value beyond the base period depends on BARDA option exercises, so contractors should distinguish the committed base funding from the maximum ceiling when assessing market impact.
- Future program milestones and option exercises may indicate whether additional follow-on or subcontracting work emerges.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Grants & Funding
**Published:** September 30, 2026

### Government Entities
- Biomedical Advanced Research and Development Authority (BARDA)
- U.S. Food and Drug Administration (FDA)

### Vendors
- SCYNEXIS (awardee)

### Sources
- [Which USD 46 million antifungal biotech just won a government contract worth up to USD 214 million?](https://kalkine.ca/news/healthcare/which-usd-46-million-antifungal-biotech-just-won-a-government-contract-worth-up-to-usd-214-million) - kalkine.ca
- [Four small biotechs, four catalysts, one USD 214 million government contract: which one is the market underpricing?](https://kalkine.ca/news/healthcare/four-small-biotechs-four-catalysts-one-usd-214-million-government-contract-which-one-is-the-market-underpricing) - kalkine.ca